Portfolio Companies – Page 18 – BioScience Managers

Destiny Pharma announces FDA Fast Track Designation for lead clinical candidate, exeporfinium chloride (XF-73)

15th March 2018/in Portfolio Companies

Posted on 15/03/2018 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights

14th March 2018/in Portfolio Companies

Announced positive topline results for the first seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving treatment success Signed a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs Completed a public offering of common stock in Jan. 2018 for […]

AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

13th March 2018/in Portfolio Companies

CATEGORY: Featured Tuesday, March 13, 2018 6:50 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “We are delighted to collaborate with the U.S. Department of Veterans Affairs on the compassionate use of AB-SA01 and AB-PA01 within the VA Palo Alto Health Care System” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage […]

Adherium’s Directors Purchase Approximately 1.4 Million Shares on the Open Market

12th March 2018/in Adherium, Portfolio Companies

12 Mar 2018 SAN MATEO, Calif., March 12, 2018 (GLOBE NEWSWIRE) — Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced that members of its Board of Directors recently purchased approximately 1.4 million shares on the open market. The timing of these purchases complied with the Company’s “blackout period” […]

Adherium Names Tim Houchin Vice President of Sales

26th February 2018/in Adherium, Portfolio Companies

26 Jan 2018 San Mateo, CA – January 26, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced Tim Houchin as Vice President of Sales. “Tim brings to our sales effort a sophisticated understanding of the intersection of wearables and healthcare as well as how to reach consumers […]

AVITA Medical Announces FDA Approval of Expansion of RECELL Compassionate Use Program in Life Threatening Injuries

12th February 2018/in Portfolio Companies

Expanded Protocol Allows Treatment of Up to 88 Patients Valencia, CA, USA, and Melbourne, Australia, 12 February 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the […]

Destiny Pharma wins Deal of the Year at the Insider South East Dealmaker Awards 2018

5th February 2018/in Portfolio Companies

Posted on 05/02/2018 Destiny Pharma has won Deal of the Year at the Insider South East Dealmakers Awards 2018, held on 1 February 2018 at The Copthorne in Gatwick, UK. Now in its twelfth year, the Dealmakers awards recognise the region’s top deals and advisory companies over the course of the last 12 months. The Deal […]

Avita Announces Five RECELL® Abstracts Accepted for Presentation at American Burn Association (ABA) 50th Annual Meeting

30th January 2018/in Portfolio Companies

Valencia, CA, USA, and Melbourne, Australia, 30 January 2018 — Avita Medical (ASX – AVH, OTCQX: AVMXY) announced that five abstracts highlighting the compelling clinical data and health economic benefits of RECELL® in the treatment of burns have been accepted for presentation at the American Burn Association 50th Annual Meeting to be held from April […]

AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

10th January 2018/in Portfolio Companies

CATEGORY: Featured Wednesday, January 10, 2018 6:00 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 shares of its common stock, offered at […]

AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock

9th January 2018/in Portfolio Companies

CATEGORY: Featured Tuesday, January 9, 2018 5:13 pm EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering. H.C. […]

Pages